Zhenghai Bio released its 2026 interim report, with net profit attributable to the parent company at 33.31 million yuan, down 27.85% from the same period last year. Total operating revenue was 160 million yuan, down 14.94% year-on-year. Net cash flow from operating activities was 28.29 million yuan, down 40.65% year-on-year. The company's latest asset-liability ratio was 9.97%, gross margin was 82.37%, return on equity was 3.81%, and diluted earnings per share was 0.19 yuan.
Yantai Zhenghai Bio-Tech Co LtdNet profit fell 27.85% year-on-year, revenue down 14.94%, and operating cash flow down 40.65%.
